Phase 3, randomized, double-blind trial of pembrolizumab in the adjuvant treatment of renal cell carcinoma (RCC): KEYNOTE-564

Powles, T.; Zhang, T.; Gurney, H.; Doshi, G.; Cobb, P.; Parnis, F.; Lee, J.L.; Park, S.H.; Semenov, A.; Chang, Y.H.; Quinn, D.I.; Wan, S.S.; Poehlein, C.; Choueiri, T.

期刊名称European Urology Supplements
作者Powles, T.; Zhang, T.; Gurney, H.; Doshi, G.; Cobb, P.; Parnis, F.; Lee, J.L.; Park, S.H.; Semenov, A.; Chang, Y.H.; Quinn, D.I.; Wan, S.S.; Poehlein, C.; Choueiri, T.
卷第17卷
期第2期
印刷ISSN1569-9056
文件大小84.43KB
发表时间2018-03
DOI10.1016/S1569-9056(18)31644-0

发现好书期刊，享受阅读乐趣

Phase 3, randomized, double-blind trial of pembrolizumab in the adjuvant treatment of renal cell carcinoma (RCC): KEYNOTE-564